Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought Phase 3 was already "ONGOING." I am not sure how some people are just willing to forget about that. SMH -Pier
I think P3 is the closest catalyst. Likely not able to start until the Fall - so still a ways away. But I think that is probably closest. But this study should be relatively quick for a P3 study. Patient in respiratory distress either lives or dies - not likely needing year follow up etc.
Will Dr. Ricordi’s very concerning issues arising from TSOI SEC filings re his work related to UofM’s 2020 P2b CV19/ARDS IND get him similarly removed (as w $TSOI) from his appointment as Principal Investigator for $CELZ cleared ImmCelz T1D IND?
DOMINOS SET TO FALL?
HISTORY REPEATS?
No word from Ricordi regarding TSOI SEC Filings since first 8K on 8/24/2022.
10/24/22 8k👇
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315222029460/form8-k.htm
Amicus Briefs/8Ks 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99.htm
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99-1.htm
2/10/23 8K👇
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315223004263/form8-k.htm
I wonder what CELZ CEO/Tim Warbington thinks about all this….
Definitely. Just a distraction from the sinking PPS & rising OS share count In My Opinion.
Seems paid consultants are hard at work, though nobody is buying the BS. Well, except StuckHolders.
It was stated on the company forum that ph3 were progressing and then Dixon made an apology statement regarding the status of ph3 trials.
Whether this was due to a delay or not it was misleading and there are screenshots of said post exchange.
I have screenshots of Dixon apologizing to investors.
I would recommend the company to focus on progression of their companies product line instead of pursuing frivolous lawsuits with disgruntled investors. This is really a sad display.
It looks like Doe #1 and Doe #4 could be the same person.
For investors and interested parties not Frightened by Facts Date/Time Filed 10/04/23 @ 03:08:26 PM or... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174129552
does addressing said go against the consultant play book
& again https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174130254
For investors and interested parties, TSOI v DOES lawsuit updates found:
1). https://roa.sdcourt.ca.gov/roa/faces/CaseSearch.xhtml
2) enter Year filed - 2023
3) enter case# 00045520
San Diego Superior Court of California
Presiding Judge:
Judge Robert P Dahlquist
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001419051/000149315224003170/form8-k.htm
https://www.facebook.com/share/p/27HGhGytUGi9cdzx/?
https://www.businesswire.com/news/home/20240122714656/en/Therapeutic-Solutions-International-Files-Lawsuit-in-San-Diego-Superior-Court-to-Obtain-Identities-of-Certain-Individuals-or-Entities
NAMED @golly(potentially of 50) as filed:
DOE #1
"CEOTimDixonisaFRAUD" and "JohnnyTrader33."
DOE #2
"Slumboar" and "Sluminem," "Bob Slumbug," and most recently VariantSlum_PartDeux.
DOE #3
"rosiebelle."
DOE #4
"TransgenderTrader."
DOE #5
"RustyMaverick."
DOE #6
"Professor_pyg."
DOE #7
"dannymac65."
Dearest Slummy/Dances with Wallstreet/ Slumboar/Doe#2,
Point to the lies. I’ll wait 😁
I see FIDUCIARY DUTY on steroids.🎯💯🚂
1st Amicus 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99.htm
Supplemental Amicus 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99-1.htm
DC AC Docket 👇
https://dockets.justia.com/docket/circuit-courts/cafc/23-2054
1/11/23 UofM Zoom meeting w/ Kenyon 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223004263/ex99-1.htm
2/10/23 8K👇
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315223004263/form8-k.htm
10/24/22 8k👇
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315222029460/form8-k.htm
ReStem’s Demonstratives 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223004263/ex99-4.htm
Where’s Danny??
Regards,
Rymung
Post all the bullshit you want. Fact is you and this company misled investors with the constant posts about an “Ongoing” Phase 3. Nothing but lies. Try to spin it anyway you want. It was a LIE!
Dear John,
Based upon TSOI SEC filings, the P2 IND/Trial led by Giancomo Lanzoni, Camillo Ricordi, Norma Sue Kenyon et al used as basis for the aforementioned FDA cleared Phase III IND - it appears the Phase III CV19/ARDS trial was cleared by FDA (honor system) but Tim Dixon/TSOI after several yrs fighting obfuscation discovered (UofM/Miller School’s P2b IND) disturbing flaws/inconsistencies.
And I quote:
“ 25. In regard to the phase 2b that was allegedly conducted using the claimed JadiCells, it’s as if they applied to FDA to conduct clinical trial in pain using 600mg ibuprofen and referenced the drug master file for ibuprofen, but in reality, gave the patients 10mg morphine, and disclosed in the scientific report the benefits were because of ibuprofen.
26. While Amici acknowledges suggesting Appellant and Appellee likely have unclean hands, this Amici supports the ruling by the PTAB for the reasons they clearly enunciated, and respectfully ask this Court to see Appellants and their motives for what they likely are – fraudulent attempts to pass off less potent stem cells that merely meet the ISCT standards for biomarkers using the JadiCell and its superior potency, but not testing to be sure it is a JadiCell that would distinguish it from these other companies like Restem and Arugula’s attempts at producing MSCs that will clear an FDA Phase 3 trial and qualify for a BLA, as TSOI set out to do when it entered into two (2) ELPAs with Appellee. Based on the foregoing, this Amici respectfully requests that the Court affirm the Board’s finding that Restem failed to carry its burden of proving that claims 1-15 of the ’176 Patent are unpatentable.
Respectfully Submitted,”
1st Amicus Brief 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99.htm
Supplemental Amicus Brief (Ibuprofen v Morphine)👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99-1.htm
1/11/23 UofM Zoom meeting informing UofM office of Technology Transfer/ Dr. Norma Sue Kenyon 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223004263/ex99-1.htm
2/10/23 8K👇
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315223004263/form8-k.htm
10/24/22 8k👇
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315222029460/form8-k.htm
ReStem’s Demonstratives 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223004263/ex99-4.htm
What will the FDA/DOJ/FBI/SEC/FINRA do with this information? Time will tell.
Guaranteed: J33, MHG, ANP CR GL NSK JP NR KM RG et al will continue to ignore. Rock - hard place.
Whilst the law sorts that mess out, TSOI filed a new ALL ARDS CAUSATION P3 IND 👍 Which would be the natural progression egardless of UofM et al’s circumstances.
need a settle down agreement by shares
Remember how many BILLIONS of shares were believed to be needed way back in the end of 2021 to fund the Phase 3 trials? Some sure do! TSOI might be almost there! Again, that’s a maybe! Enjoy…
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167045706
I wonder? How far into the future will the "mean time" extend?
• Fri Oct 08, 2021 5:14 pm
"however in the mean time"
2021 to the present:
https://www.barchart.com/stocks/quotes/TSOI/interactive-chart
Maybe the poster being quoted is some kind of Oracle?
Telling all, to not let you hard earned money sit idle......No......in fact, not idle, but DEVALUING while retirement propertieS were being acquired at the Old Fishing Hole???
The Opportunity Cost with this "investment" from Oct. 21 to present are incalculable.
The fact is, if you let your money sit idle for 3 or more years and it then shoots to the moon, those 3 or more years are still filed away in the Loss to Opportunity Cost column.
Some folks will never let themselves see that.
One of if not my favorite user post from the $TSOI forum! Interesting!! Accurate!!!
4realz
Re: Painful Investment
• Fri Oct 08, 2021 5:14 pm
Most rewarding investment ever!!! .. working my way through the knowledge and IP here, learning about the science behind it, the scientists, the progression of many treatments of many ailments is quite possibly one of the best investments I have ever made and I owe a lot of what I learned to TSOl; Tim Dixon, Thomas Ichim, Franco Maricola, Camillo Ricordi, Amit Patel.
... the list goes on and on ..
The financial side of TSOl as an investor will come with time; success. I hope you can get as much out of this investment as I have to date if in nothing more than an education. I know the goal is to make the money here and see financial returns as soon as possible, and we will, however in the mean time I will be getting as much info out of this amazing team as possible.
Then reap the rewards some day... stay strong ladies and gents, trust the science, trust Tim; I do.
btw I’d like you to be able to convince / persuade any & all the investing public your spin.
Damn mo’ verifiable Facts https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174129008
That must scare some to address eh RyRy
You gotta come with something man. No I do not earn money here. I have lost well way too much
u do not earn from tsoi? sorry for that
here he goes board came here a week ago to test the waters and now has to spew his paid BS to all. The facts remain.
Well thats a complete BS statement "For quite some time, over years, a specific group of online users across multiple social media platforms, have claimed TSI insiders “dumped shares” illegally (amongst myriad other fabrications) w/out reporting per SEC requirements."
Is that what Dixons case is riding on. HAHA
Interesting! Skipping P2!! Amazing…
https://www.fiercebiotech.com/biotech/roche-places-stronger-gates-phase-3-pipeline-reduce-failure-rate
“The CEO blamed part of this downturn in late-stage clinical success rates on Tecentriq, where there had been a “push to go directly into phase 3, skipping phase 2, in order to catch up.” Tecentriq is one of many immune checkpoint inhibitors that got caught up in a PD-1/L1 land grab as Merck & Co.'s Keytruda rose to prominence.”
How are they “skipping Phase 2” at all? Well now…because they can. And so can TSOI.
HAHAHA Mother Theresa would have died laughing at this pos. People here care about heir money and how much we all have lost believing the lies.
haha right nothing to see there while they dilute this into oblivion.
Phase 3 was a straight up lie remember!!!
https://stocktwits.com/rosiebelle/message/550996897
(I have to show you the factual posts from stocktwits since your banned from there ...or suspended whatever)
Look here We all know this is a pure share selling operation a scam as you will, I do not answer to some weak poster who spams the boards with crap information till they are banned (STOCKTWITS RING A BELL THERE GUY) I won't do your own homework for you.
I have no boss. Sorry. there is no conspiracy just a scumbag CEO who lied and committed fraud. but you already knew that.
Might I remind you of the facts of what these POS people behind this scam did to investors. Your right in the thick of it and best believe its coming. Tick tock.
who is Kyle Shepard...https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174129008
just continue to report him.
Q: How many shares did TSOI sell/issue ie dilution for capital resources from Feb 9th 2021 through say September 29th 2021?
Did TSOI rake in MILLIONS of $$$? Is that what you’re (not “your” - boss man PP will spank you for YOUR grammatical errors naughty boy) insinuating?
We know insiders didn’t sell a single share. So there goes YOUR narrative regarding ANY insider profits.
SEC filings are publicly available to all. Even you.
Oddly, you seem very resistant to accessing/reviewing SEC filings.
Why? They won’t bite. I promise.
Perhaps ask BBWMHG, as he likely posted the applicable 10Q’s for that period. 👍
He may ignore 🔥🎯evidence of Patel’s involvement in very troubling matters, but he’s all over TSOI share issuance. Selective guy.
Or…..surprise me and do YOUR OWN DD (novel concept)
Here you go!
https://www.sec.gov/edgar/browse/?CIK=1419051&owner=exclude
Do report your findings, Doe#1 🤓
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174125003
Since RyRy seems to not want to address my multiple queries …I said screenshots were forthcoming. Simply facts as screenshots do not lie, pump or bash; they just provide indisputable facts.
Perhaps now we can have robust & truthful conversations as to why their has been a continuing PPS decline.
Would TSI’s Ph 3 All Cause Phase III IND be the most significant projected catalyst??
https://therapeuticsolutionsint.com/therapeutic-solutions-international-files-to-initiate-phase-iii-clinical-trial-for-acute-respiratory-distress-syndrome-ards-leveraging-positive-covid-19-data-with-jadicell-stem-cell-therapy/
Or do investors see other opportunities in the near/mid term that rival such an epic UC-Stem Cell/Regenerative Lung opportunity?
Something with:
https://mynanostilbene.com/
Or
https://campbellneurosciences.com/
Or
https://ctebiologics.com/
Or
https://breathebiologics.com/
Or maybe
https://www.resnovabiologics.com//
Much to review. Very exciting family of companies!
Interesting!!
Outstanding DD…SEC 👍👍👍
Rafael Gonzalez, PhD, Founder / Chief Development & Science Officer of Restem, LLC., was on the JadiCell patent in 2010!!
Yet, Restem never mentioned it. Interesting!
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99-1.htm
“6. In my previous Amicus Brief, entered and accepted on August 30, 2023, Amici described to the court how the lawyers from Restem, LLC, as well as the lawyers from Jadi Cell, LLC (“Jadi Cell”), failed to notice the PTAB of the lengthy, ongoing, business, research, and clinical relationships between all of these parties and their members. After additional research and investigation conducted by myself, I have discovered the following that should benefit the Court in its appellate review.
7. The history of the ‘176 patent is unusual, to say the least, from a drug developers’ perspective.
It begins in June of 2010 with the publication of a peer reviewed scientific article titled "An Efficient
Approach to Isolation and Characterization of Pre- and Postnatal Umbilical Cord Lining Stem Cells for
Clinical Applications" and the authors of this paper are: R. Gonzalez, L. Griparic, M. Umana, K. Burgee, V. Vargas, R. Nasrallah, F. Silva, and A. Patel. The authors describe a population of cells that can be extracted and cultured from umbilical cord tissue and defined as “Umbilical Cord Lining Stem Cells”. Later it was discovered that there were issues with these cells and additional research was done leading to a second peer reviewed paper being published in 2013 titled "Mesenchymal Stem Cell Population Isolated From the Subepithelial Layer of Umbilical Cord Tissue" with the authors listed as: Amit N. Patel, Vanessa Vargas, Patricia Revello, and David A. Bull.
8. In between the two events Patel filed a provisional patent application (No. 61/582,070) on Dec. 30, 2011, with provisional application No. 61/591,211, also filed by Patel on Jan. 26, 2012, titled "Methods and Compositions for the Clinical Derivation of an Allogenic Cell and Therapeutic Uses" and was Granted U.S. Patent No.: 9,803,176 B2 on Oct. 31, 2017, which is the subject of the IPR and this appeal.
9. In my first amici brief I stated “Jadi not only failed to notify TSOI in a timely manner of the filing of the IPR as was their obligation under the EPLA, but consistently failed to communicate or provide progress reports of the litigation. Most egregious, Jadi Cell failed to inform amici or TSOI of the prior (current) relationship between Ricordi and Restem. Amici had to learn of it through its own research.” In particular, many of these people from both Restem, Jadi Cell, University of Miami (“UM”), and Arugula Sciences, LLC (“Arugula”) have all known each other going back as far as 2010. The authors of the 2010 paper are: R. Gonzalez, L. Griparic, M. Umana, K. Burgee, V. Vargas, R. Nasrallah, F. Silva, and A. Patel. A. Patel is Amit Patel, sole member of Jadi Cell LLC; R. Gonzalez is none other than Rafael Gonzalez, PhD, Founder / Chief Development & Science Officer of Restem, LLC. On August 12, 2021, Dr. Ricordi, on UM letterhead sent to the FDA a Letter of Authorization (LOA) for Arugula Sciences, LLC (managing member being Neil Riordan at the time) to reference and rely on IND 19757 in support of Arugula’s IND applications for Muscular Dystrophies, Eosinophilic Disorders, and Sarcoidosis. Dr. Ricordi and UM had no “Rights of Reference” to allow others to use the licensed JadiCell without TSOI’s express permission.”
SEC filings are most interesting>>>>>>>>>>>>>>>>>>>>>>>>>>
Here's a line from one of them:
"As of the date of this filing, GHS has been issued 541,632,207 shares of Common ..." (The date for this is there also)
That is from the opening page of https://www.otcmarkets.com/filing/html?id=17237897&guid=Yad-kacHN5wfJth
Now let's refer to a post from BBW, just today:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174125507
Until this is brought under control, everything else is taken as MISDIRECTION In My Opinion.
-Don’t read SEC filings-. Is that what this board and its moderators insinuate?
Libel, defame, threaten and curse.
A petulant child’s approach, yes?
How will that look if/when legal sprawl from Stocktwits occurs?
Why? Why attack such an amazing company selling at ATL’s?
Are there many OTC’s with 79 patent applications and Phase 3 assets and more??
Who are the moderators allowing continued libel, defamation, disparagement?
Better question: For whom?
Mother Teresa would beam with envy over their unselfish mission to right their unsubstantiated wrongs.
DOES 1-7 and friends seem very nervous tor a group that has loads of “proof” of their very disturbing claims. I find that very interesting.
Let review the heart of the matter by their own body of work - “Wen EUA?” “Wen CTDG”
Fiduciary Duties. Tim Dixon takes them seriously. Investors rightly applaud him for his diligence.
1st Amicus 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99.htm
Supplemental Amicus 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99-1.htm
1/11/23 UofM Zoom meeting w/ Dr. Kenyon 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223004263/ex99-1.htm
2/10/23 8K👇
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315223004263/form8-k.htm
10/24/22 8k👇
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315222029460/form8-k.htm
ReStem’s Demonstratives 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223004263/ex99-4.htm
That last one from ReStem’s lawyers is 🔥🔥🔥🔥
No proof of “claimed cells”.. . OUCH!! A bonus for that legal team. Then what did Patel give Ricordi in 2020?? Same as MTA /Jadicell in 2018?? I wonder.
OS 4 billion. Yes. Double what it was in 2021.Would BBWPPJboiSlummy rather a 1:2 RS?
That cuts it all in half. Float too. And expands AS.
I don’t see them clamoring for an RS anymore….i wonder why?
HEY, Look over here! Pay no attention to the growing OS count.
For quite some time, over years, a specific group of online users across multiple social media platforms, have claimed TSI insiders “dumped shares” illegally (amongst myriad other fabrications) w/out reporting per SEC requirements.
A) how did “they” come to gain this knowledge?
B) where is their proof of such a serious charge?
C) where is THEIR lawsuit?
That’s malicious, libelous, defamatory and frankly, disgusting. And as detailed, part of TSOI’s 1st amended complaint brought by TSOI/Tim Dixon/Thomas Ichim in California State Superior Court v DOES 1-50, FYI.
Judge Dahlquist reviewed Plaintiff’s complaint, and ruled Ex Parte, as follows:
SUPERIOR COURT OF CALIFORNIA, COUNTY OF SAN DIEGO NORTH COUNTY MINUTE ORDER
DATE: 03/20/2024
TIME: 08:30:00 AM
DEPT: N-29
JUDICIAL OFFICER PRESIDING: Robert P Dahlquist
CLERK: Tina Horak
REPORTER/ERM: Not recorded
BAILIFF/COURT ATTENDANT: S. Mora
CASE NO: 37-2023-00045520-CU-DF-NC CASE INIT.DATE: 10/19/2023
CASE TITLE: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC VS DOES 1-50 [IMAGED] CASE CATEGORY: Civil - Unlimited
CASE TYPE: Defamation
EVENT TYPE: Ex Parte…
Court and counsel confer…
The ex-parte is granted.
The Court authorizes the issuance of the subpoena with modifications of an Independant 3rd party.
Plaintiff requests to continue the upcoming civil case management hearing.
Civil Case Management Conference is continued pursuant to party's motion to 06/28/2024 at 11:00AM
before Judge Robert P Dahlguist.
IT IS SO ORDERED.
Judge Robert P Dahlquist
DATE: 03/20/2024
DEPT: N-29
MINUTE ORDER
https://roa.sdcourt.ca.gov/roa/faces/CaseSearch.xhtml
SDSC of California
2023 case# 00045520
Judge Robert P Dahlquist
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001419051/000149315224003170/form8-k.htm
https://www.facebook.com/share/p/27HGhGytUGi9cdzx/?
https://www.businesswire.com/news/home/20240122714656/en/Therapeutic-Solutions-International-Files-Lawsuit-in-San-Diego-Superior-Court-to-Obtain-Identities-of-Certain-Individuals-or-Entities
DOE’s # 1-7: @Stocktwits screen names:
DOE #1
"CEOTimDixonisaFRAUD" and "JohnnyTrader33."
DOE #2
"Slumboar" and "Sluminem," "Bob Slumbug," and most recently VariantSlum_PartDeux.
DOE #3
"rosiebelle."
DOE #4
"TransgenderTrader."
DOE #5
"RustyMaverick."
DOE #6
"Professor_pyg."
DOE #7
"dannymac65."
" #Pacer was an ugly car " I remember taking a Road Trip in Pacer's Ugly Brother, The Gremlin. 3 spd on the floor with Slotted Rims. 🤣
SS increases again Authorized Shares 6,500,000,000 03/18/2024
Outstanding Shares 4,153,512,083 03/18/2024
Restricted 1,386,707,118 03/18/2024
Unrestricted 2,766,804,965 03/18/2024
Held at DTC 2,716,357,138 03/18/2024
Updated SS Increases Authorized Shares 6,500,000,000 02/27/2024
Outstanding Shares 4,054,204,583 02/27/2024 >195,340,422
Restricted 1,366,707,118 02/27/2024 >41,000,000
Unrestricted 2,687,497,465 02/27/2024 >154,340,422
Held at DTC 2,637,049,638 02/27/2024 >154,340,422
Timothy G. Dixon Solely Responsible as the CEO’s signature attest to
discounted dilution
Right on Cue Authorized Shares 5,500,000,000 02/06/2024
Outstanding Shares 3,858,864,161 02/06/2024 >56,197,188
Restricted 1,325,707,118 02/06/2024
Unrestricted 2,533,157,043 02/06/2024 >56,197,183
Held at DTC 2,482,709,216 02/06/2024 >56,197,183
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173935237
btw since the below was never answered who is Kyle Shepard
Correct...at the moment.
Distractions will not cancel out the selling. JMO
https://ctebiologics.com/index.php/ind-27377/
Another Subsidiary launched by TSOI.
Licensed TSOI Intellectual Property:
Investigational New Drug Application #27377 titled as: Investigation of Umbilical Cord-derived Mesenchymal Stem Cells for the Treatment of Chronic Traumatic Encephalopathy Patients.
On May 23, 2023, the Company announced the forming of CTE Biologics, Inc. On July 05, 2023, the Company signed license agreements with CTE Biologics for the exclusive use of US Patent Publication No.: 20220125852 titled as: "Protection and Regeneration of Neurological Function by Using Stem Cells" as well as the sale and transfer of Investigational New Drug Application titled as:
Investigation of Umbilical Cord derived
Mesenchymal Stem Cells for the Treatment of Chronic Traumatic Encephalopathy Patients.
A Total of 2,500,000 Shares Of Restricted Common Stock
Purchase Price per Share: $2.00
Minimum Purchase: 10,000 Shares
Aggregate Purchase Price (if all Shares Are Sold):
$5,000,000
Pre-Offering Common Shares 23,050,000
Post-Offering Common Shares 25,550,000
https://therapeuticsolutionsint.com/
more and more
Who is Dr. Giancomo Lanzoni?
Most notably, Lanzoni is the lead author of the 2020 UofM Ph 2b CV19/ARDS IND published paper that preceded the now hotly discussed UofM Miller School of Medicine FDA cleared Ph 3 IND, purchased in March of 2022 by TSOI.
https://diabetesresearch.org/giacomo-lanzoni/
https://stemcellsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/sctm.20-0472
https://therapeuticsolutionsint.com/therapeutic-solutions-international-completes-purchase-of-fda-phase-iii-jadicell-stem-cell-investigational-new-drug-application-from-university-of-miami/
Impressive young man. What does Dr. Lanzoni think of these TSOI SEC filings?
1st Amicus Brief
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99.htm
Supplemental Amicus Brief
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99-1.htm
DCFCofA Docket
https://dockets.justia.com/docket/circuit-courts/cafc/23-2054
1/11/23 UofM Zoom meeting w/ Fellow P2b author Dr. Norma Sue Kenyon/UofM Office of Technology Transfer
https://www.sec.gov/Archives/edgar/data/1419051/000149315223004263/ex99-1.htm
2/10/23 8K
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315223004263/form8-k.htm
10/24/22 8k
https://www.sec.gov/ix?doc=/Archives/edgar/data/1419051/000149315222029460/form8-k.htm
ReStem’s Demonstratives 👇
https://www.sec.gov/Archives/edgar/data/1419051/000149315223004263/ex99-4.htm
Houston….Miami has a problem.
“fraudulent attempts to pass off less potent stem cells”
26. While Amici acknowledges suggesting Appellant and Appellee likely have unclean hands, this Amici supports the ruling by the PTAB for the reasons they clearly enunciated, and respectfully ask this Court to see Appellants and their motives for what they likely are – fraudulent attempts to pass off less potent stem cells that merely meet the ISCT standards for biomarkers using the JadiCell and its superior potency, but not testing to be sure it is a JadiCell that would distinguish it from these other companies like Restem and Arugula’s attempts at producing MSCs that will clear an FDA Phase 3 trial and qualify for a BLA, as TSOI set out to do when it entered into two (2) ELPAs with Appellee. Based on the foregoing, this Amici respectfully requests that the Court affirm the Board’s finding that Restem failed to carry its burden of proving that claims 1-15 of the ’176 Patent are unpatentable.
Respectfully Submitted,
/// /// ///
_______________________ Timothy G. Dixon, Amici
https://www.sec.gov/Archives/edgar/data/1419051/000149315223045887/ex99-1.htm
Noted 👇👇👇👇👇
2. I am the author of this Supplemental Amicus Curiae brief and have personal knowledge of each fact stated herein except as to those matters stated as knowledge based on information and belief, and as to those matters I am informed and believe them to be true and correct. Costs associated with the filing of the Motion for Leave and the Amicus Curiae Brief have been paid by TSOI.
Good morning! ☀️
Some information about TSOI’s 1st launched subsidiary, Campbell Neurosciences.
https://campbellneurosciences.com/patents/
CEO/Dr. Thomas Ichim
https://www.businesswire.com/news/home/20230327005388/en/
CNSI Dividend offering/SEC filing
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001419051/000149315223008958/form8-k.htm
https://www.otcmarkets.com/filing/html?id=16514967&guid=l6T-kqT8my2mB3h#ex99-3_htm
CNSI main website
https://campbellneurosciences.com/
Campbell Score
https://therapeuticsolutionsint.com/therapeutic-solutions-international-launches-campbell-neurosciences-division-aimed-at-biologically-identifying-and-repairing-suicide-prone-brains/
https://vimeo.com/528727833/8f23f4a40f
Followers
|
527
|
Posters
|
|
Posts (Today)
|
16
|
Posts (Total)
|
63525
|
Created
|
10/04/08
|
Type
|
Free
|
Moderators BigBadWolf JMC$ Yooperman |
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
OCEANSIDE, Calif., Dec. 9, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.
The experiments, which involved exposing mice to established stressors, demonstrated that specific areas of the brain associated with production of new brain cells are damaged by stress. In agreement with previously published research, administration of fluoxetine (Prozac™) protected the brain from stress-induced damage. Surprisingly, QuadraMune™ administration appeared superior to Prozac™ at stimulating proliferation of new brain cells.
"QuadraMune™ which is currently in a clinical trial for prevention of COVD-191, has also been demonstrated to possess anti-inflammatory activity in other clinical trials, suppressing cytokines such as IL-62, which are known to be involved in depression3 and suicide4" said Kalina O'Connor, Director of Campbell Neurosciences and co-inventor on the patent. "Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune™ for preventing suicide."
"Although much enthusiasm has been generated over the planned distribution of the COVID vaccine, at present little is being done to address mental health issues that are being exacerbated by the current pandemic" said Dr. James Veltmeyer, co-inventor of the patent, and Chief Medical Officer of the Company. "If current results are reproducible, the possibility that a nutraceutical would concurrently boost immunity while preserving mental health is highly enticing."
"It has not escaped us that COVID-19 is associated with increased inflammatory cytokines in the blood of patients, cytokines that also predispose to depression" said Famela Ramos, Vice President of Business Development for the Company. "It may be that the recent increase in suicides and suicide attempts is related biologically to activities of the coronavirus. It will be interesting to examine whether QuadraMune™ may modify putative negative mental effects of the virus."
"An estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all U.S. adults" stated Timothy Dixon, President and CEO of the Company. "We believe the Mission of our Company is not just providing a return on investment to our shareholders, but also increasing the quality of life for Americans. We are extremely pleased to report this unexpected finding with significant potential implications to advancing non-toxic means of helping patients with this terrible condition."
1 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19 | BioSpace
3 Ting et al. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194.
4 O'Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |